Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Bioxyne.
RELATED STOCKHEAD STORIES
Health & Biotech
Bioxyne subsidiary unveils platform for transparent pricing in Australia’s B2B medical cannabis market
Health & Biotech
The ASX stocks hoping to profit from the endless search for an ‘elixir of youth’
Health & Biotech
Why these ASX firms are shying away from the ‘pot stock’ label – Part One
News
Quarterly Wrap: Pot stocks shine with record revenues for Melodiol, 75pc increase in revenue for Bioxyne
News
In Case You Missed It: O&G production, a graphite plant and a Chilean gold anomaly
Health & Biotech
Bioxyne subsidiary imports $3.2million of premium quality cannabis flower into Australia
News
Top 10 at 11: Not a lot of movement, but there’s not a whole lot of news.
Health & Biotech
These are the ASX stocks Morgans thinks can push the health and wellness agenda
Health & Biotech
Bioxyne embraces AI revolution with B2B marketplace JV targeting expansion of Australia’s cannabis industry
News
ASX Small Caps Lunch Wrap: Who else has been left running for their lives this week?
News
ASX Quarterly Wrap: Bioxyne revenue jumps following BLS acquisition, iCandy cash receipts climb
Health & Biotech
MDMA and magic mushrooms have arrived: Australia lets psychs find a new way for happy to fight sad
Health & Biotech
Bioxyne’s Dr Watson brand extends its Amazon footprint into US and Japan
Tech
These tech and pharma stocks are looking to M&A to drive growth in global markets
Health & Biotech
Check Up: M&A activity in healthcare heats up as Aussie biotech Kinoxis attracts $181m from big pharma
Health & Biotech
Stock Insiders: Bioxyne acquires Breathe Life Sciences with consumer favourite brand Dr Watson
Health & Biotech
